Noacid Control (Pantoprazole Sodium Sesquihydrate)

Pantoprazole, the active ingredient in Noacid Control, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid secretion and is indicated for conditions such as gastro‑esophageal reflux disease, erosive esophagitis, NSAID‑induced gastric ulcer and as part of Helicobacter pylori eradication therapy.

GNH USA supplies Noacid Control as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole acts on the gastric proton pump to lower acid production, making it useful for several acid‑related disorders. - Gastro‑esophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. - Erosive esophagitis: facilitates mucosal repair by decreasing gastric acidity. - NSAID‑induced gastric ulcer: protects the gastric lining and supports ulcer healing. - Helicobacter pylori eradication (as part of combination therapy): enhances the effectiveness of antibiotic regimens by maintaining a less acidic environment.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Diarrhea - Nausea - Abdominal pain

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Clostridioides difficile‑associated diarrhea - Low magnesium levels (hypomagnesemia)

Before initiating therapy, consider the following precautions: - Assess renal function: adjust use in severe impairment. - Monitor magnesium levels: especially during long‑term treatment. - Review concomitant medications: avoid known contraindicated drugs such as rilpivirine. - Use caution in pregnancy: prescribe only if benefit outweighs potential risk. - Store at room temperature: keep in the original pack, protect from moisture.

Pantoprazole may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption and efficacy. - Methotrexate: increased toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Digoxin: potential rise in serum levels. - Diazepam: may increase sedation and plasma concentration.